Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-45 (canceled)

Claim 46 (new) A pharmaceutical composition comprising:

(a) a salt form of an API having an aqueous solubility less than about 10 mg/mL in gastric fluid conditions;

(b) a precipitation retardant; and

(c) an optional enhancer;

wherein the composition retards crystallization or precipitation of the API for at least 5 minutes in gastric fluid conditions.

Claim 47 (new) The pharmaceutical composition according to claim 46, wherein the precipitation retardant is a surfactant.

Claim 48 (new) The pharmaceutical composition according to claim 46, wherein the precipitation retardant is a surfactant and exhibits an interfacial tension of less than about 10 dyne/cm or a surface tension of less than about 42 dyne/cm.

Claim 49 (new) The pharmaceutical composition according to claim 46, wherein the precipitation retardant is a poloxamer.

Claim 50 (new) The pharmaceutical composition according to claim 46, wherein the composition comprises an enhancer.

Claim 51 (new) The pharmaceutical composition according to claim 46, wherein the composition comprises HPC or HPMC as an enhancer.

Claim 52 (new) The pharmaceutical composition according to claim 46, wherein crystallization or precipitation is retarded for at least 20 minutes.

Claim 53 (new) The pharmaceutical composition according to claim 46, wherein crystallization or precipitation is retarded for at least 40 minutes.

Claim 54 (new) The pharmaceutical composition according to claim 46, wherein crystallization or precipitation is retarded for at least 60 minutes.

Claim 55 (new) The pharmaceutical composition according to claim 46, wherein the API is a sulfonamide.

Claim 56 (new) The pharmaceutical composition according to claim 46, wherein the API is a benzene sulfonamide.

Claim 57 (new) The pharmaceutical composition according to claim 46, wherein the API is celecoxib, deracoxib, valdecoxib, rofecoxib or eturicoxib.

Claim 58 (new) The pharmaceutical composition according to claim 46, wherein the salt form of the API is an alkali metal or alkaline earth metal salt.

Claim 59 (new) The pharmaceutical composition according to claim 46, wherein the salt form of the API is a sodium, potassium, lithium, or calcium salt.

Claim 60 (new) The pharmaceutical composition according to claim 46, wherein the bioavailability of the composition orally administered is at least 70%.

Claim 61 (new) The pharmaceutical composition according to claim 46, wherein the bioavailability of the composition orally administered is as least 80%.

Claim 62 (new) The pharmaceutical composition according to claim 46, wherein the bioavailability of the composition orally administered is as least 90%.

Claim 63 (new) The pharmaceutical composition according to claim 46, wherein the C_{max} is at least 2 fold greater than a neutral form in vivo or in an in vitro dissolution assay.

Claim 64 (new) The pharmaceutical composition according to claim 46, wherein the C_{max} is at least 4 fold greater than a neutral form in vivo or in an in vitro dissolution assay.

Claim 65 (new) The pharmaceutical composition according to claim 46, wherein the C_{max} is at least 10 fold greater than a neutral form in vivo or in an in vitro dissolution assay.

Claim 66 (new) The pharmaceutical composition according to claim 46, wherein the bioavailability of the composition is at least 50% greater than a neutral form.

Claim 67 (new) The pharmaceutical composition according to claim 46, wherein the bioavailability of the composition is at least 2 fold that of a neutral form.

Claim 68 (new) The pharmaceutical composition according to claim 46, wherein the bioavailability of the composition is at least 5 fold that of a neutral form.

Claim 69 (new) A process for producing a pharmaceutical composition for delivering a supersaturated concentration of a drug having an aqueous solubility less than about 10 mg/mL in gastric fluid conditions, which process comprises intimately mixing together components:

(a) a salt form of an API having an aqueous solubility less than about 10 mg/mL in gastric fluid conditions;
(b) a precipitation retardant; and
(c) an optional enhancer.

Claim 70 (new) The process for producing a pharmaceutical composition according to claim 69, wherein the API is a sulfonamide.

Claim 71 (new) The process for producing a pharmaceutical composition according to claim 69, wherein the API is a benzene sulfonamide.

Claim 72 (new) The process for producing a pharmaceutical composition according to claim 69, wherein the API is celecoxib, deracoxib, valdecoxib, rofecoxib or eturicoxib.

Claim 73 (new) The process for producing a pharmaceutical composition according to claim 69, wherein the salt form of the API is an alkali metal or alkaline earth metal salt.

Claim 74 (new) The process for producing a pharmaceutical composition according to claim 69, wherein the salt form of the API is a sodium, potassium, lithium, or calcium salt.